Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Envista Holdings (NVST – Research Report), Augmedix (AUGX – Research Report) and Cochlear Limited (CHEOF – Research Report).
Envista Holdings (NVST)
J.P. Morgan analyst Rachel Vatnsdal maintained a Buy rating on Envista Holdings on February 8 and set a price target of $29.00. The company’s shares closed last Friday at $21.94, close to its 52-week low of $20.00.
According to TipRanks.com, Vatnsdal is a 1-star analyst with an average return of
Currently, the analyst consensus on Envista Holdings is a Hold with an average price target of $24.38, which is an 8.6% upside from current levels. In a report issued on February 9, Stifel Nicolaus also maintained a Buy rating on the stock with a $25.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Augmedix (AUGX)
Benchmark Co. analyst Bill Sutherland reiterated a Buy rating on Augmedix today and set a price target of $7.00. The company’s shares closed last Friday at $4.34.
According to TipRanks.com, Sutherland has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Augmedix with a $7.00 average price target, a 61.3% upside from current levels. In a report issued on January 29, Maxim Group also reiterated a Buy rating on the stock.
Cochlear Limited (CHEOF)
In a report issued on February 8, David Low from J.P. Morgan maintained a Hold rating on Cochlear Limited, with a price target of A$295.00. The company’s shares closed last Friday at $205.54, close to its 52-week high of $217.46.
According to TipRanks.com, Low is a 2-star analyst with an average return of
Currently, the analyst consensus on Cochlear Limited is a Moderate Sell with an average price target of $185.30, a -8.9% downside from current levels. In a report released today, Morgans also downgraded the stock to Hold with a A$290.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVST:
- Envista downgraded to Hold from Buy at Jefferies
- Envista price target lowered to $23 from $24 at Piper Sandler
- Envista downgraded to Market Perform after earnings miss at William Blair
- Envista downgraded to Market Perform from Outperform at William Blair
- Envista sees FY24 core revenue up in low-single digits, consensus $2.59B
